Valneva Reports Revenue of €174.7 Million in 2025 and Prepares Crucial Data on Its Lyme Disease Vaccine
The biopharmaceutical group Valneva has released its preliminary results for 2025, marked by stable revenue and strengthened cash reserves. The year 2026 is set to be pivotal with the anticipation of the first Phase 3 results for its Lyme disease vaccine candidate, in partnership with Pfizer.
Valneva achieved a revenue of €174.7 million in 2025, up from €169.6 million in 2024. Product sales reached €157.9 million compared to €163.3 million the previous year, reflecting a 42.3 percent decline in third-party product sales to €19.2 million. However, non-third-party product sales grew by 9 percent at constant exchange rates. The vaccination group consolidated its financial position with cash reserves of €109.7 million as of December 31, 2025, compared to €168.3 million a year earlier. This cash position was bolstered by a successful refinancing of current debt. The release also mentions a variable consideration related to the research and license agreement for the Lyme disease program.
Outlook for 2026
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
For the fiscal year 2026, Valneva expects revenue between €155 and €170 million, with product sales projected at €145 to €160 million. The lower sales forecast for 2026 reflects continued growth of established commercial brands, offset by the gradual reduction of third-party product sales. The year is expected to be formative with the anticipated disclosure in the first half of the first Phase 3 results for the Lyme disease vaccine candidate, followed by regulatory submissions by Pfizer, subject to positive data. The group also anticipates initial Phase 2 data for its tetravalent shigellosis vaccine candidate, with a decision on next steps expected in the second half of the year. Valneva is committed to rigorous cash management with further reduction in operational consumption, while maintaining investments in research and development.
Leadership and Governance
The Board of Directors has renewed the mandate of CEO Thomas Lingelbach for a new three-year period, subject to shareholder approval at the 2026 general meeting. This reappointment ensures continuity as the group enters a new phase of development.
Au troisième trimestre, nous avons continué à nous concentrer sur le renforcement de notre trésorerie, ce qui nous a permis de refinancer notre dette à des conditions financières plus avantageuses.
Chiffre d’affaires de 127,0 millions d’euros sur neuf mois (+8,9 %), ventes de 119,4 millions d’euros, trésorerie de 143,5 millions d’euros au 30/09/2025, perte nette 65,2 millions d’euros, EBITDA ajusté (37,7) millions d’euros. Guidance 2025 confirmée : chiffre d’affaires attendu entre 165 et 180 millions d’euros; ventes attendues entre 155 et 170 millions d'euros. Renforcement de la position financière via refinancement et ATMs; Phase 3 VALOR pour le vaccin Lyme en cours selon calendrier.
Risks mentioned
Suspension de la licence IXCHIQ ® aux États-Unis par la FDA (impact sur ventes segment voyageurs)
Risque de résultats cliniques défavorables pour les candidats (phase 3 VALOR pour Lyme, essais S4V2, VLA1601 incertitudes réglementaires)
Exposition aux fluctuations de change (impact négatif mentionné de 1,3 millions d’euros sur ventes, effets de change volontaires)
Dépendance à des partenaires de distribution et diminution des produits de tiers (arrêt de distribution de Rabipur/RabAvert et Encepur)
Opportunities identified
Résultats positifs potentiels de la Phase 3 VALOR (VLA15) pouvant mener à des demandes d'autorisation en 2026
Accord commercial avec CSL Seqirus en Allemagne pour stimuler la commercialisation des vaccins
Croissance des ventes d'IXCHIQ ® sur les marchés hors États-Unis et dans les PRFI (livraisons de substance active)
Potentiel du candidat S4V2 contre la shigellose (marché estimé > 500 millions de dollars/an)
Données positives de Phase 1 pour VLA1601 (Zika) et forte persistance d'anticorps pour IXCHIQ ® (95 % à 4 ans) comme avantage concurrentiel
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
